Company profile
Acumen Pharmaceuticals, Inc.
NASDAQ: ABOS · Healthcare · Biotechnology
PublicHQ Newton, VACIK 0001576885Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 37DQ —GM —SS 47
v0.1 · 35/100 weight · pillars only
↑ market scale, balance-sheet leverage · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$121.3M
Employees
61
as of 2026-08-14
Market cap
$184.2M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$121.3M-$121.3M2025
Operating income-$123.8M-$123.8M2025
Total assets$122.8M$122.8M2025
Liabilities$52.4M$52.4M2025
Equity$70.4M$70.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Acumen Pharmaceuticals, Inc.’s financial profile?
Acumen Pharmaceuticals, Inc. earned -$121.3M in FY2025 net income.
Peers · Healthcare
PepGen Inc.——Cardiol Therapeutics Inc.——Atrium Therapeutics, Inc.——Organigram Global Inc.——Conexeu Sciences Inc.——Tenaya Therapeutics, Inc.——Key facts
CEODaniel J. O'Connell
SectorHealthcare
IndustryBiotechnology
HeadquartersNewton, VA
ExchangeNASDAQ: ABOS
Employees61
IPO date2021-07-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.